Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

EMANATE: badanie setmelanotydu u pacjentów ze specyficznymi wariantami genów w szlaku MC4R

19 października 2026 zaktualizowane przez: Rhythm Pharmaceuticals, Inc.

Faza 3, randomizowane, podwójnie ślepe, kontrolowane placebo badanie: wiele niezależnych badań cząstkowych setmelanotydu u pacjentów z wariantami genów POMC/PCSK1, LEPR, NCOA1 (SRC1) lub SH2B1 w szlaku receptora melanokortyny-4

The protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in participants with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor pathway:

  • Pro-opiomelanocortin (POMC) or proprotein convertase subtilisin/kexin type 1 (PCSK1; Sub-study 035a)
  • Leptin receptor (LEPR; Sub-study 035b)
  • Nuclear receptor coactivator 1 (NCOA1; steroid receptor coactivator 1 [SCR1]; Sub-study 035c)
  • Steroid receptor coactivator-1 homology 2 B adapter protein 1 (SH2B1; Sub-study 035d)

The objectives and endpoints are identical for these sub-studies.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

296

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

      • Lyon, Francja, 69677
        • GH Est Hopital Femme Mere Enfant
      • Paris, Francja, 75651
        • Hu Pitie Salpetriere Aphp
      • Paris, Francja, 75771
        • Hopital Armand Trousseau
      • Pessac, Francja, 33604
        • Centre Hospitalier Universitaire (CHU) de Bordeaux
      • Saint-Denis, Francja, 97400
        • Hôpital Félix Guyon Bellepierre
      • Toulouse, Francja
        • CHU de Toulouse Hopital des Enfants
      • Rio, Grecja, 26504
        • University of Patras School of Medicine
      • Barcelona, Hiszpania, 08950
        • Hospital Sant Joan de Deu, Barcelona
      • Cadiz, Hiszpania
        • Puerta del Mar University Hospital
      • Madrid, Hiszpania, 28040
        • Hospital Fundación Jimenez Díaz
      • Málaga, Hiszpania, 29010
        • Hospital Universitario Virgen de la Victoria de Málaga
      • Valencia, Hiszpania, 46014
        • Hospital General de Valencia
      • Rotterdam, Holandia, 3015 GD
        • Erasmus Medisch Centrum
      • Petah Tikva, Izrael, 49372
        • Hasharon Hospital
      • Ramat Gan, Izrael, 52621
        • Chaim Sheba MC, Safra Children's Hospital
    • Alberta
      • Edmonton, Alberta, Kanada, T6G 2E1
        • University of Alberta - Alberta Diabetes Institute (ADI)
    • Ontario
      • Toronto, Ontario, Kanada, M5G 1X8
        • The Hospital for Sick Children
      • Berlin, Niemcy, 10117
        • Charite - Universitatsmedizin Berlin
      • Frankfurt, Niemcy, 60596
        • Endokrinologikum Frankfurt
      • Leipzig, Niemcy, 04103
        • Universitaetsklinikum Leipzig
      • Ulm, Niemcy, 89075
        • Universitaetsklinikum Ulm
      • San Juan, Portoryko, 00925-253
        • University of Puerto Rico
      • San Juan, Portoryko, 00927
        • Puerto Rico Consortium for Clinical Investigation, Inc.
    • Arizona
      • Phoenix, Arizona, Stany Zjednoczone, 85016
        • Phoenix Children's Hospital
      • Scottsdale, Arizona, Stany Zjednoczone, 85258
        • HonorHealth Bariatric Center
    • California
      • Los Angeles, California, Stany Zjednoczone, 90027
        • Children's Hospital Los Angeles
    • Colorado
      • Aurora, Colorado, Stany Zjednoczone, 80045
        • Children's Hospital Colorado
    • Connecticut
      • New Haven, Connecticut, Stany Zjednoczone, 06519
        • Yale Center for Clinical Investigation
    • Florida
      • Altamonte Springs, Florida, Stany Zjednoczone, 32701
        • Advent Health
      • Gainesville, Florida, Stany Zjednoczone, 32610
        • University of Florida
    • Georgia
      • Suwanee, Georgia, Stany Zjednoczone, 30024
        • InQuest Medical Research
    • Massachusetts
      • Worcester, Massachusetts, Stany Zjednoczone, 01655
        • UMASS Memorial Medical Center
    • Michigan
      • Ann Arbor, Michigan, Stany Zjednoczone, 48105
        • University of Michigan
      • Dearborn, Michigan, Stany Zjednoczone, 48126-2619
        • Metro Detroit Endocrinology Center
    • Minnesota
      • Rochester, Minnesota, Stany Zjednoczone, 55902
        • Mayo Clinic
    • Mississippi
      • Madison, Mississippi, Stany Zjednoczone, 39110
        • Mississippi Center for Advanced Medicine
    • Missouri
      • Chesterfield, Missouri, Stany Zjednoczone, 63017
        • St. Luke's Hospital
      • Kansas City, Missouri, Stany Zjednoczone, 64108
        • Children's Mercy
      • St Louis, Missouri, Stany Zjednoczone, 63130
        • Washington University in St. Louis
    • New York
      • Buffalo, New York, Stany Zjednoczone, 14260
        • University of Buffalo
      • New York, New York, Stany Zjednoczone, 10032
        • Columbia University
      • New York, New York, Stany Zjednoczone, 10029
        • Mount Sinai Hospital
      • New York, New York, Stany Zjednoczone, 10029
        • Metropolitan Hospital Center
      • Staten Island, New York, Stany Zjednoczone, 10306
        • Ten's Medical Center - Pediatric Endocrinology Clinic
    • Ohio
      • Cincinnati, Ohio, Stany Zjednoczone, 45229
        • Cincinnati Children's Hospital Medical Center
      • Cleveland, Ohio, Stany Zjednoczone, 44195
        • Cleveland Clinic
    • Oregon
      • Portland, Oregon, Stany Zjednoczone, 97239
        • Oregon Health & Science University
    • Pennsylvania
      • Danville, Pennsylvania, Stany Zjednoczone, 17822
        • Geisinger Clinic
      • Philadelphia, Pennsylvania, Stany Zjednoczone, 19104
        • Children's Hospital of Philadelphia
      • Pittsburgh, Pennsylvania, Stany Zjednoczone, 15213
        • UPMC Montefiore
    • Tennessee
      • Nashville, Tennessee, Stany Zjednoczone, 37232
        • Vanderbilt University School of Medicine
    • Texas
      • Amarillo, Texas, Stany Zjednoczone, 79106
        • Texas Tech
      • Houston, Texas, Stany Zjednoczone, 77030
        • Texas Children's Hospital
      • Houston, Texas, Stany Zjednoczone, 77084
        • Biopharma Informatic
      • McAllen, Texas, Stany Zjednoczone, 78503
        • Rio Grande Valley Endocrine Center
      • Plano, Texas, Stany Zjednoczone, 75093
        • Endocrine Associates of Dallas and Plano
    • Washington
      • Tacoma, Washington, Stany Zjednoczone, 98405
        • MultiCare Health System Institute for Research and Innovation
    • West Virginia
      • Morgantown, West Virginia, Stany Zjednoczone, 26506
        • West Virginia University
    • Wisconsin
      • Marshfield, Wisconsin, Stany Zjednoczone, 54449
        • Marshfield Clinic Research Foundation, a Division of Marshfield Clinic, Inc
      • Bristol, Zjednoczone Królestwo, BS2 8AE
        • Bristol Royal Hospital for Children
      • Cambridge, Zjednoczone Królestwo, CB2 0QQ
        • University of Cambridge
      • Liverpool, Zjednoczone Królestwo, L9 7AL
        • Aintree University Hospital
      • London, Zjednoczone Królestwo, W2 1NY
        • Imperial College Healthcare Trust
      • London, Zjednoczone Królestwo, NW1 2PG
        • London Medical - The London Diabetes Centre
      • London, Zjednoczone Królestwo, WC1E6JF
        • University College London Hospitals NHS Foundation Trust
      • Manchester, Zjednoczone Królestwo, M13 9WL
        • Manchester Children's Hospital

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

6 lat do 65 lat (Dziecko, Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Participants must have a pre-identified:

    • Heterozygous genetic variant in the POMC gene or PCSK1 gene
    • Heterozygous genetic variant in the LEPR gene
    • Homozygous, heterozygous, or compound heterozygous variant in the NCOA1 (SRC1)
    • Homozygous, heterozygous, or compound heterozygous variant in SH2B1 gene, or chromosomal 16p11.2 deletion encompassing the SH2B1 gene
  • Between 6 and 65 years of age at the time of provision of informed consent/assent

  • Obesity, defined as body mass index (BMI) ≥30 kg/m^2 for participants ≥18 years of age or BMI ≥95th percentile for age and gender for participants 6 up to 17 years of age

  • Participant and/or parent or guardian is able to understand and comply with the requirements of the study and is able to understand and sign the written informed consent/assent

  • Participant and/or parent or guardian reports that participant experienced childhood obesity, defined as the participant and/or parent or guardian reporting that the participant had obesity or was significantly overweight during childhood

  • Agree to use a highly effective form of contraception throughout the study and for 90 days following the study

  • Reported history of lifestyle intervention of diet and exercise

  • Symptoms or behaviors of hyperphagia persistent during the participant's life, including manifestations in childhood, as determined by the Investigator at screening.

Key Exclusion Criteria:

  • Weight loss of 2% or greater in the previous 3 months
  • Bariatric surgery or procedure within the previous 6 months
  • Significant psychiatric disorder(s)
  • Suicidal ideation, attempt or behavior
  • Clinically significant pulmonary, cardiac, endocrine/metabolic, hepatic or oncologic disease
  • Glycated hemoglobin (HbA1C) >10% at Screening
  • History of significant liver disease or severe kidney disease
  • History or close family history (parents or siblings) of melanoma, or participant history of oculocutaneous albinism
  • Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions (excluding non-invasive basal or squamous cell lesion)
  • Participation in any clinical study with an investigational drug/device within 3 months prior to the first day of dosing
  • Previously enrolled in a clinical study involving setmelanotide or any previous exposure to setmelanotide
  • Significant hypersensitivity to any excipient in the study drug
  • If female, pregnant or breastfeeding

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Potroić

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: POMC or PCSK1 variant

1:1 Randomization

Subcutaneous Injection

Subcutaneous Injection

Eksperymentalny: LEPR variant

1:1 Randomization

Subcutaneous Injection

Subcutaneous Injection

Eksperymentalny: NCOA1 (SRC1) variant

1:1 Randomization

Subcutaneous Injection

Subcutaneous Injection

Eksperymentalny: SH2B1 variant

1:1 Randomization

Subcutaneous Injection

Subcutaneous Injection

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Treatment Period: Percent Change From Baseline in Body Mass Index (BMI)
Ramy czasowe: Baseline, Week 52

BMI was calculated using participant's weight and height assessments as weight in kilograms (kg)/(height in meters [m])^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration. An analysis of covariance (ANCOVA) model was used to calculate the least-squares mean with randomization stratification factors and baseline value as a covariate.

Baseline, Week 52

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Treatment Period: Percentage of Participants Who Achieved at Least a 5% Reduction in Baseline BMI
Ramy czasowe: Baseline, Week 52

BMI was calculated using participant's weight and height assessments as weight in kg/(height in m)^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants Aged ≥18 Years): Percent Change From Baseline in Body Weight
Ramy czasowe: Baseline, Week 52

Data reported are for mean percent change from baseline in body weight measured in kg. Baseline was defined as the last available measurement taken prior to the start of treatment administration

Baseline, Week 52
Treatment Period (Participants Aged ≥12 Years): Percent Change From Baseline in Weekly Average Most Hunger Score
Ramy czasowe: Baseline, Week 52

Participants ≥12 years of age who were able to validly and reliably self-report were administered "Hunger Questions for Participants ≥12 Years of Age©." The 'most hunger' item was designed to be evaluated separately and was averaged on a weekly basis. Participants were asked 'In the last 24 hours, how hungry did you feel when you were the most hungry?' and rated their hunger on an 11-point numeric rating scale ranging from 0 to 10 (0 = not hungry at all and 10 = hungriest possible). Data reported are for mean percent change from baseline in the weekly average daily most hunger score. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period: Percentage of Participants Who Achieved at Least a 10% Reduction in Baseline BMI
Ramy czasowe: Baseline, Week 52

BMI was calculated using participant's weight and height assessments as weight in kg/(height in m)^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants <18 Years): Percent Change From Baseline in BMI Z-score
Ramy czasowe: Baseline, Week 52

BMI z-scores were calculated according to the Centers for Disease Control and Prevention (CDC) Growth Charts and according to participant's gender and age at screening. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease in BMI Z-score (< 0) indicates a reduction in BMI from Baseline whereas an increase in BMI-Z score (> 0) indicated an increase in BMI from Baseline. Data reported are for mean percent change from baseline in BMI Z-score. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants <18 Years): Percent Change From Baseline in BMI 95th Percentile
Ramy czasowe: Baseline, Week 52

The percentage change from baseline in BMI 95th percentile was calculated as ([BMI at Week 52 / BMI 95th percentile]) - [BMI at baseline / BMI 95th percentile])*100. BMI percentile scores are measures of relative weight adjusted for child age and gender. The percent of the BMI 95th percentile score expresses the participant's BMI as a percentage of the Centers for Disease Control (CDC) 95th percentile reference population. Data reported are for mean percent change from baseline in BMI 95th percentile. Baseline was defined as the most recent measurement prior to the first administration of study drug.

Baseline, Week 52
Treatment Period: Percent Change From Baseline in Waist Circumference
Ramy czasowe: Baseline, Week 52

The waist circumference (in centimeters [cm]) was measured according to the National Heart, Lung, and Blood Institute (NHLBI) criteria. Data reported are for mean percent change from baseline in waist circumference. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Ramy czasowe: Baseline up to 60 weeks

TEAEs were defined as any untoward medical occurrence temporally associated with the use of study treatment, whether or not considered related to the study treatment that happened on or after the date of the first study treatment administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Baseline up to 60 weeks
Treatment Period (Participants ≥18 Years): Percent Change From Baseline in Physical Functioning Score on the Impact of Weight on Quality of Life (IWQOL)-Lite
Ramy czasowe: Baseline, Week 52

The IWQOL-Lite is a validated 31-item self-reported measure of obesity-specific quality of life questionnaire. The physical function domain comprised 11 items which had 5 response items: Always True=5, Usually True=4, Sometimes True=3, Rarely True=2, Never True=1. The score of each item was summed to calculate the raw score. The raw score range of the physical function domain was 11-55 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in physical functioning score on the IWQOL-Lite. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Physical Comfort Score on the IWQOL-Kids-Parent-Proxy
Ramy czasowe: Baseline, Week 52

The IWQOL-Kids-Parent-Proxy is a psychometrically validated 27-item self-reported measure of obesity-specific quality of life questionnaire. The physical comfort domain comprised 6 items which used a 5-point Likert scale: Always True=1, Usually True=2, Sometimes True=3, Rarely True=4, Never True=5. The items were summed to calculate the raw score. The raw score range of the physical function domain was 6-30 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in Physical Comfort Score on the IWQOL-Kids-Parent-Proxy. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants ≥18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Lite
Ramy czasowe: Baseline, Week 52

The IWQOL-Lite is a validated 31-item self-reported measure of obesity-specific quality of life questionnaire which comprised of 5 domains (physical function, self-esteem, sexual life, distress and work) and had 5 response items: Always True=5, Usually True=4, Sometimes True=3, Rarely True=2, Never True=1. The items were summed to calculate the raw total score. The raw total score range was 31-155 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in Impact on Quality of Life Total Score on the IWQOL-Lite. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-Proxy
Ramy czasowe: Baseline, Week 52

The IWQOL-Kids-Parent-Proxy is a psychometrically validated 27-item self-reported measure of obesity-specific quality of life questionnaire and comprised of 4 domains (physical comfort, body esteem, social life, family relations) and used a 5-point Likert scale: Always True=1, Usually True=2, Sometimes True=3, Rarely True=4, Never True=5. The items were summed to calculate the raw total score. The raw total score range was 27 to 135 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-Proxy. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period: Percent Change From Baseline in Body Weight in Setmelanotide Initial Responders Versus Placebo
Ramy czasowe: Baseline, Week 52

Initial responders were defined as setmelanotide treated participants with ≥5% body weight loss (≥18 years of age) or a decrease in BMI by ≥3% (<18 years of age) at the time of consecutive 12 weeks with the increased 3.0 mg/day or with final increased dose level. Data reported are for mean percent change from baseline in body weight measured in kg. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Krzesło do nauki: David Meeker, MD, Rhythm Pharmaceuticals, Inc.

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

26 kwietnia 2022

Zakończenie podstawowe (Rzeczywisty)

19 grudnia 2025

Ukończenie studiów (Rzeczywisty)

30 czerwca 2026

Daty rejestracji na studia

Pierwszy przesłany

30 września 2021

Pierwszy przesłany, który spełnia kryteria kontroli jakości

13 października 2021

Pierwszy wysłany (Rzeczywisty)

26 października 2021

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

12 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

19 października 2026

Ostatnia weryfikacja

1 października 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • RM-493-035

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

produkt wyprodukowany i wyeksportowany z USA

Tak

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .